Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Current therapy for Parkinson's disease

https://doi.org/10.14412/2074-2711-2014-3-80-84

Full Text:

Abstract

The main goal of therapy for Parkinson's disease (PD) is to correct dopamine deficiency in the nigrostriatal system. Levodopa preparations and dopamine receptor agonists (DRAs) that are prescribed with regards to patient age and disease severity are mainly used now. Notwithstanding the fact that levodopa preparations are the gold standard of therapy, their long-term use gives rise to complications as motor fluctuations and drug-induced dyskinesias. The currently available DRAs are the drugs of choice for the therapy of early-stage PD as they are as effective as levodopa preparations. In extensive-stage PD, DRAs are used to enhance the therapy and correction of developed motor fluctuations and dyskinesias. Pramipexole is one of the most commonly used representatives of non-ergoline DRAs. The paper analyzes the efficacy of the medication used as both monotherapy and part of combined therapy, its effect on tremor and depression in PD. A novel extended-release formulation of pramipexole is considered separately. Both immediate- and extended-release pramipexole formulations contain the same active ingredient and have the same dopamine-receptor interaction profile, but differ in the tablet release rate of the active ingredient. The advantages of the novel formulation are its more steady-state plasma concentration and 24-hour action, which ensures continuous dopaminergic stimulation of
postsynaptic receptors to prevent and treat already developed motor complications. The once-daily extended-release formulation of the drug makes its treatment regimen easier and patient compliance higher.

About the Author

A. V. Obukhova
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation

Moscow, Russia 8, Trubetskaya St., Build. 2, Moscow 119991



References

1. Артемьев ДВ. Эволюция дофаминергической терапии болезни Паркинсона. В кн.: Болезнь Паркинсона и расстройства движений. Руководство для врачей. Под ред. С.Н. Иллариошкина, Н.Н. Яхно. Москва: НЦН РАМН; 2008. С. 147–50. [Artem'ev DV. Evolution of dofaminergic therapy of an illness of Parkinson. In: Bolezn' Parkinsona i rasstroistva dvizhenii. Rukovodstvo dlya vrachei [Parkinson's

2. illness and disorders of the movements. The guide for doctors]. Illarioshkin SN, Yakhno NN, etidors. Moscow: NTsN RAMN; 2008. P. 147–50.]

3. Claveria LE, Calne DB, Allen JG. «On-off» phenomena related to high plasma levodopa. Br Med J. 1973;2(5867):641–3. DOI: http://dx.doi.org/10.1136/bmj.2.5867.641.

4. Tolosa ES, Martin WE, Cohen HP, Jacobson RL. Patterns of clinical response and plasma dopa levels in Parkinson's disease. Neurology. 1975 Feb;25(2):177–83. DOI: http://dx.doi.org/10.1212/WNL.25.2.177.

5. Quinn N, Parkes JD, Marsden CD. Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology. 1984 Sep;34(9):1131–6. DOI: http://dx.doi.org/10.1212/WNL.34.9.1131.

6. Федорова НВ, Кулуа ТК. Опыт применения прамипексола в лечении болезни Паркинсона. Consilium Medicum. 2007;9(2):103–7. [Fedorova NV, Kulua TK. Experience of application of a pramipeksol in treatment of an illness of Parkinson. Consilium Medicum. 2007;9(2):103–7. (In Russ.)]

7. Яхно НН, Нодель МР, Федорова НВ и др. Эффективность и переносимость прамипексола (Мирапекса) при продолжительной терапии у пациентов с болезнью Паркинсона. Неврологический журнал. 2004;9(3):25–30. [Yakhno NN, Nodel' MR, Fedorova NV, et al. Efficacy and tolerance of pramipexol (mirapex) in long-term therapy of patients with Parkinson's disease. Nevrologicheskii zhurnal. 2004;9(3):25–30. (In Russ.)]

8. Иллариошкин СН, Иванова-Смоленская ИА, Загоровская ТБ и др. Семилетний опыт применения Мирапекса у больных с различными формами первичного паркинсонизма. Журнал неврологии и психиатрии им. С.С. Корсакова. 2006;106(11):1–8. [Illarioshkin SN, Ivanova-Smolenskaya IA, Zagorovskaya TB, et al. Seven years’ experience of application of Mirapeks for patients with various forms of primary parkinsonism. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2006;106(11):1–8. (In Russ.)]

9. Reichmann H, Brecht MH, Kö ster J, at al. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson’s disease. CNS Drugs. 2003;17(13):965–73. DOI: http://dx.doi.org/10.2165/00023210-200317130-00003.

10. Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring, agonist useful in treating Parkinson’s disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141–51.

11. Hauser RA, McDermott MP, Messing S, et al. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol. 2006;63:1756–60. DOI: http://dx.doi.org/10.1001/archneur.63.12.1756.

12. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease. A randomized controlled trial. JAMA. 2000;284:1931–8. DOI: http://dx.doi.org/10.1001/jama.284.15.1931.

13. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61:1044–53.

14. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49:162–8. DOI: http://dx.doi.org/10.1212/WNL.49.1.162.

15. Moller JC, Oertel WH, Koster J, et al. Long-term efficacy and safety of pramipexole in advanced Parkinson’s disease: results from a European multicenter trial. Mov Disord. 2005;20(5):602–10. DOI: http://dx.doi.org/10.1002/mds.20397.

16. Weiner WJ, Factor SA, Jankovic J, et al. The long-term safety and efficacy of pramipexole in advanced Parkinson’s disease. Parkinsonism Relat Disord. 2001;7(2):115–20. DOI: http://dx.doi.org/10.1016/S1353-8020(00)00031-6.

17. Иллариошкин СН. Возможности агониста дофаминовых рецепторов прамипексола в лечении болезни Паркинсона. Неврология, нейропсихиатрия, психосоматика. 2012;(2):78–83. [Illarioshkin SN. Capacities of the dopamine receptor agonist pramipexole in the treatment of patients with Parkinson’s disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2012;(2):78–83. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711- 2012-389.

18. Левин ОС, Бойко АН, Нестерова ОС и др. Влияние агониста дофаминовых рецепторов прамипексола (мирапекса) на тремор, аффективные нарушения и качество жизни у больных с болезнью Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2010;110(2):39–44. [Levin OS, Boiko AN, Nesterova OS, et al. Effect of dopamine agonist pramipexole (mirapex) on tremor, ffective disorders and quality of life in patients with Parkinson’s disease. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2010;110(2):39–44. (In Russ.)]

19. Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry. 2002;72:713–20. DOI: http://dx.doi.org/10.1136/jnnp.72.6.713.

20. Артемьев ДВ. Лечение болезни Паркинсона в молодом возрасте. Неврология, нейропсихиатрия, психосоматика. 2010;(3):6–11. [Artem’ev DV. Treatment of Parkinson's disease at a young age. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2010;(3):6–11. (In Russ.)]. DOI: http://dx.doi.org/10.14412/ 2074-2711-2010-93.

21. Нодель МР. Депрессия при болезни Паркинсона. Неврология, нейропсихиатрия, психосоматика. 2010;(4):11–7. [Nodel’ MR. Depression in Parkinson’s disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2010;(4):11–7. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2010-110.

22. Нодель МР, Яхно НН. Мирапекс (прамипексол) в лечении недвигательных нарушений при болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2008;108(5):32–8. [Nodel’ MR, Yakhno NN. Mirapex (pramipexole) in the treatment of nonmotor disturbances in Parkinson’s disease. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2008;108(5):32–8. (In Russ.)]

23. Barone P, Scarzella L, Antonini A, et al. Pramipexole versus sertraline in the treatment of depression in Parkinsons disease. J Neurol. 2005;4:1–7.

24. Lemke MP, Brecht HM, Koester JK, et al. Anhedonia, depression, and motor functioning in Parkinsons disease during treatment with Pramipexole. J Neuropsych Clin Neurosci. 2005;17(2):214–20. DOI: http://dx.doi.org/10.1176/appi.neuropsych. 17.2.214.

25. Левин ОС, Тумгоева АИ. Применение новой лекарственной формы агониста дофаминовых рецепторов прамипексола в лечении болезни Паркинсона. Справочник поликлинического врача. 2011;(8):53–7. [Levin OS, Tumgoeva AI. Application of a new dosage form of an agonist of dopamine receptors of a pramipeksol in treatment of an illness of Parkinson. Spravochnik poliklinicheskogo vracha. 2011;(8):53–7. (In Russ.)]

26. Antonini A, Calandrella D. Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients. Neuropsychiatr Dis Treat. 2011;7:297–302. DOI: http://dx.doi.org/10.2147/NDT.S10097.

27. Eisenreich W, Sommer B, Hartter S, Jost WH. Pramipexole extended release: a novel treatment option in Parkinson’s disease. Parkinsons Dis. 2010;2010:612–9. DOI: 10.4061/2010/612619.

28. Обухова АВ. Опыт применения прамипексола пролонгированного действия при болезни Паркинсона. Эффективная фармакотерапия. 2013;23:4–11. [Obukhova AV. Experience of using long-acting pramipexole in patients with Parkinson`s disease. Effektivnaya farmakoterapiya. 2013;23:4–11. (In Russ.)]

29. Обухова АВ, Артемьев ДВ. Новая пролонгированная лекарственная форма прамипексола в лечении болезни Паркинсона. Эффективная фармакотерапия. 2012;(4):14–8. [Obukhova AV, Artem’ev DV. The new prolonged dosage form of a pramipeksol in treatment of an illness of Parkinson. Effektivnaya farmakoterapiya. 2012;(4):14–8. (In Russ.)]

30. Hauser RA, Schapira AH, Rascol O. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson’s disease. Mov Disord. 2010 Nov 15;25(15):2542–9. DOI: http://dx.doi.org/10.1002/mds.23317.

31. Poewe W, Barone P, Hauser RA, et al. Pramipexole extended-release is effective in early Parkinson’s disease. Movt Disord. 2009;24(Suppl 1):S273.

32. Hauser RA, Schapira AH, Barone P, et al. Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson’s disease. Eur J Neurol. 2014 May;21(5):736–43. DOI: http://dx.doi.org/10.1111/ene.12375.

33. Poewe W, Rascol O, Barone P. Extendedrelease pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology. 2011 Aug 23;77(8):759–66. DOI: http://dx.doi.org/10.1212/WNL. 0b013e31822affb0.

34. Schapira A, Barone P, Hauser RA, et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 2011 Aug 23;77(8):767–74. DOI: http://dx.doi.org/10.1212/WNL.0b013e31822affdb.

35. Hauser RA, Gordon MF, Mizuno Y, et al. Minimal clinically important difference in Parkinson’s disease as assessed in pivotal trials of pramipexole extended release. Parkinsons Dis. 2014. DOI: http://dx.doi.org/10.1155/2014/467131.

36. Rascol O, Barone P, Hauser RA. Efficacy, safety, and tolerability of overnight switching from immediate – to once daily extended-release pramipexole in early Parkinson’s disease. Mov Disord. 2010 Oct 30;25(14):2326–32. DOI: http://dx.doi.org/10.1002/mds.23262.

37. Тумгоева АИ, Шиндряева НН, Левин ОС. Приверженность к терапии больных с болезнью Паркинсона. Уральский медицинский журнал. 2011;(10):58–62. [Tumgoeva AI, Shindryaeva NN, Levin OS. Patient compliance with Parkinson’s disease. Ural’skii meditsinskii zhurnal. 2011;(10):58–62. (In Russ.)]

38. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001 Aug;23(8):1296–310. DOI: http://dx.doi.org/10.1016/S0149-2918(01)80109-0.

39. Grosset КА, Bone I, Grosset D. Suboptimal medication adherence in Parkinson’s disease. Mov Disord. 2005;20(11):1502–7. DOI: http://dx.doi.org/10.1002/mds.20602.

40. Schapira AH, Barone P, Hauser RA, et al. Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson’s disease. Eur J Neurol. 2013 Jan;20(1):50–6. DOI: http://dx.doi.org/10.1111/j.1468-1331.2012.03712.x.

41. Белоусов ДЮ, Афанасьева ЕВ, Ефремова ЕА. Фармакоэкономический анализ применения противопаркинсонических препаратов в режиме монотерапии на ранних стадиях болезни Паркинсона. Качественная клиническая практика. 2013;(1):27–43. [Belousov DYu, Afanas'eva EV, Efremova EA. The farmacoekocomical analysis of application the antiparkinsonic preparations in the monotherapy mode at early stages of an illness of Parkinson. Kachestvennaya klinicheskaya praktika. 2013;(1):27–43. (In Russ.)]


For citation:


Obukhova A.V. Current therapy for Parkinson's disease. Neurology, Neuropsychiatry, Psychosomatics. 2014;6(3):80-84. (In Russ.) https://doi.org/10.14412/2074-2711-2014-3-80-84

Views: 971


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)